Premium
R‐split‐ CHOP chemotherapy for elderly patients with diffuse large B‐cell lymphoma
Author(s) -
Kreher Stephan,
Lammer Felicitas,
Augustin Dieter,
Pezzutto Antonio,
Baldus Claudia D.
Publication year - 2014
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/ejh.12304
Subject(s) - medicine , vincristine , rituximab , chemoimmunotherapy , chop , cyclophosphamide , regimen , lymphoma , diffuse large b cell lymphoma , prednisolone , chemotherapy , surgery , doxorubicin , gastroenterology , oncology
Objectives Chemoimmunotherapy with cyclophosphamide, doxorubicin, vincristine, prednisolone, and rituximab (R‐ CHOP ) is the standard of care for patients with diffuse large B‐cell lymphoma ( DLBCL ). However, management of elderly patients is challenging as critical comorbidities often account for increased number of treatment‐related complications. Patients and methods In the past 8 yrs, we have treated elderly patients with a full‐dose R‐ CHOP regimen by splitting the administration of cyclophosphamide and doxorubicin over 2 days (R‐split‐ CHOP ) to reduce peak plasma level. Here, we retrospectively analyzed the results of 30 patients with newly diagnosed DLBCL . Results The overall response rate was found to be 87%, the overall survival probability after 3 yrs was 60.6% (95% CI , 42.1%–79.0%), and the progression‐free survival probability was 49.7% (95% CI , 30.4%–68.9%). Grade 3/4 infectious complications were reported in 30% of patients, yet no treatment‐related deaths occurred. Conclusion We suggest that R‐split‐ CHOP could be a valuable option to safely administer full‐dose‐intensity R‐ CHOP to elderly patients at risk of treatment‐related complications.